Dr. Reddy's Laboratories Limited — Biomedical Watch V2

Traitements4programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
DRL_RIThis study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL\_RI or one of two sources of rituximab (Rituxan® or MabThera®). Patients will also be monitored for safety, B cell depletion and recovery, and for the development of immune responses to the administered study drugs	SEP	Phase 1/2	Immunomodulation	India, Ukraine	À vérifier
MabTheraThis study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL\_RI or one of two sources of rituximab (Rituxan® or MabThera®). Patients will also be monitored for safety, B cell depletion and recovery, and for the development of immune responses to the administered study drugs	SEP	Phase 1/2	Immunomodulation	India, Ukraine	À vérifier
RituxanThis study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL\_RI or one of two sources of rituximab (Rituxan® or MabThera®). Patients will also be monitored for safety, B cell depletion and recovery, and for the development of immune responses to the administered study drugs	SEP	Phase 1/2	Immunomodulation	India, Ukraine	À vérifier
DRL_RIThis study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL\_RI or one of two sources of rituximab (Rituxan® or MabThera®). Patients will also be monitored for safety, B cell depletion and recovery, and for the development of immune responses to the administered study drugs	SEP	Phase 1/2	Immunomodulation	India, Ukraine	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
DRL_RI	SEP	Phase 1/2	NCT02296775	Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.